Please assess the completion status of the following clinical trial:

Trial Title: Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Severe congenital hemophilia A or B with an inhibitor.~* History of frequent spontaneous bleeding episodes.~* Male, age 18 or older.~* Affirmation of informed consent with signature confirmation before any trial-related activities.~Exclusion Criteria:~* Receiving prophylaxis treatment.~* Previous participation in a clinical trial evaluating a modified rFVIIa agent.~* Known positive antibody to FVII or FVIIa detected by central laboratory at screening.~* Have a coagulation disorder other than hemophilia A or B.~* Significant contraindication to participation.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1a (Type: EXPERIMENTAL): Coagulation Factor VIIa variant, 18 µg/kg by intravenous route
- Part 1b (Type: EXPERIMENTAL): Coagulation Factor VIIa variant, 30 µg/kg by subcutaneous route
- Part 2 (Type: EXPERIMENTAL): Coagulation Factor VIIa variant, 30, 60, 90, 120 µg/kg by subcutaneous route

Based on this trial design, predict the completion outcome and termination type (if applicable).